Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
18.0M
Short interest
settlement 2026-10-15
7.6
Days to cover
-0.8 days vs prior
48.4%
Short share of volume
2026-11-02
466
Fails to deliver
settlement 2026-08-25
Mon 11 Jan
Next earnings
estimated date
-$114K
Insider flow, 90 days
0 buys, 1 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in SNDX is 18,001,644 shares, down 2,658,805 shares over the last month. Over the last 48 readings it ranged from 10,603,810 shares (15 November 2024) to 25,622,767 shares (14 November 2025). At the reported average volume of 2.4M shares a day that is 7.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/sndx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 18,001,644 | -1.3% | 2,357,123 | 7.64 |
| 2026-09-30 | 18,234,880 | -11.7% | 2,152,633 | 8.47 |
| 2026-09-15 | 20,660,449 | -4.7% | 1,402,785 | 14.73 |
| 2026-08-31 | 21,681,907 | -5.3% | 1,103,630 | 19.65 |
| 2026-08-14 | 22,902,431 | +1.1% | 1,523,998 | 15.03 |
| 2026-07-31 | 22,665,216 | +8.9% | 1,219,747 | 18.58 |
| 2026-07-15 | 20,816,110 | -4.6% | 2,116,901 | 9.83 |
| 2026-06-30 | 21,812,785 | +9.9% | 2,548,139 | 8.56 |
| 2026-06-15 | 19,855,525 | +19.4% | 2,181,350 | 9.10 |
| 2026-05-29 | 16,637,071 | -23.4% | 1,038,230 | 16.02 |
| 2026-05-15 | 21,712,664 | +9.1% | 2,060,200 | 10.54 |
| 2026-04-30 | 19,911,327 | -5.0% | 1,572,796 | 12.66 |
| 2026-04-15 | 20,968,088 | +1.3% | 1,375,680 | 15.24 |
| 2026-03-31 | 20,695,810 | +1.0% | 1,518,825 | 13.63 |
| 2026-03-13 | 20,485,613 | -6.0% | 1,519,980 | 13.48 |
| 2026-02-27 | 21,798,656 | -1.4% | 1,097,779 | 19.86 |
| 2026-02-13 | 22,117,950 | +4.6% | 1,239,118 | 17.85 |
| 2026-01-30 | 21,147,220 | -5.4% | 1,228,314 | 17.22 |
| 2026-01-15 | 22,344,466 | -1.0% | 1,391,105 | 16.06 |
| 2025-12-31 | 22,569,116 | -1.1% | 1,239,627 | 18.21 |
| 2025-12-15 | 22,826,193 | -9.5% | 1,829,420 | 12.48 |
| 2025-11-28 | 25,221,608 | -1.6% | 2,369,303 | 10.65 |
| 2025-11-14 | 25,622,767 | +1.1% | 3,377,745 | 7.59 |
| 2025-10-31 | 25,344,944 | +15.1% | 4,277,770 | 5.92 |
| 2025-10-15 | 22,023,042 | -3.4% | 2,008,777 | 10.96 |
| 2025-09-30 | 22,807,077 | -1.4% | 2,077,847 | 10.98 |
| 2025-09-15 | 23,141,658 | +10.6% | 1,812,371 | 12.77 |
| 2025-08-29 | 20,917,832 | +1.5% | 2,143,881 | 9.76 |
| 2025-08-15 | 20,605,895 | -13.8% | 3,668,680 | 5.62 |
| 2025-07-31 | 23,902,315 | +0.9% | 1,755,548 | 13.62 |
| 2025-07-15 | 23,691,424 | -0.7% | 1,786,601 | 13.26 |
| 2025-06-30 | 23,867,422 | +8.5% | 2,241,776 | 10.65 |
| 2025-06-13 | 22,003,021 | -4.9% | 1,429,117 | 15.40 |
| 2025-05-30 | 23,140,140 | +6.5% | 2,690,542 | 8.60 |
| 2025-05-15 | 21,733,924 | +0.3% | 3,350,562 | 6.49 |
| 2025-04-30 | 21,658,971 | +2.3% | 1,608,351 | 13.47 |
| 2025-04-15 | 21,168,861 | +9.3% | 2,271,679 | 9.32 |
| 2025-03-31 | 19,362,696 | +2.9% | 1,414,477 | 13.69 |
| 2025-03-14 | 18,823,847 | -2.0% | 2,207,492 | 8.53 |
| 2025-02-28 | 19,204,822 | -10.9% | 2,187,508 | 8.78 |
| 2025-02-14 | 21,551,361 | -2.9% | 2,519,652 | 8.55 |
| 2025-01-31 | 22,203,752 | -0.8% | 2,230,792 | 9.95 |
| 2025-01-15 | 22,376,587 | +5.0% | 1,937,193 | 11.55 |
| 2024-12-31 | 21,312,691 | +30.2% | 3,148,848 | 6.77 |
| 2024-12-13 | 16,364,167 | +13.7% | 2,026,529 | 8.07 |
| 2024-11-29 | 14,396,481 | +35.8% | 2,171,496 | 6.63 |
| 2024-11-15 | 10,603,810 | -0.5% | 2,616,764 | 4.05 |
| 2024-10-31 | 10,657,597 | +1.4% | 652,306 | 16.34 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of SNDX volume is 48.4%, up 2.9 points over the last five sessions. Over the last 30 readings it ranged from 15.3% (27 October 2026) to 90.3% (23 October 2026). The latest reading is in line with the 30-session average of 49.9%, on 1.0M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 504K | 1.0M | 48.4% | 54 |
| 2026-10-30 | 443K | 1.1M | 40.6% | 0 |
| 2026-10-29 | 2.3M | 2.9M | 80.1% | 0 |
| 2026-10-28 | 328K | 738K | 44.5% | 100 |
| 2026-10-27 | 185K | 1.2M | 15.3% | 0 |
| 2026-10-26 | 353K | 774K | 45.6% | 0 |
| 2026-10-23 | 3.1M | 3.4M | 90.3% | 1 |
| 2026-10-22 | 269K | 854K | 31.5% | 2,000 |
| 2026-10-21 | 479K | 1.1M | 43.2% | 582 |
| 2026-10-20 | 424K | 1.1M | 37.5% | 200 |
| 2026-10-19 | 554K | 840K | 66.0% | 0 |
| 2026-10-16 | 482K | 997K | 48.3% | 0 |
| 2026-10-15 | 550K | 915K | 60.1% | 0 |
| 2026-10-14 | 839K | 1.4M | 61.3% | 19,596 |
| 2026-10-13 | 1.8M | 3.2M | 57.6% | 137,915 |
| 2026-10-12 | 201K | 455K | 44.1% | 0 |
| 2026-10-09 | 192K | 463K | 41.4% | 0 |
| 2026-10-08 | 266K | 551K | 48.3% | 0 |
| 2026-10-07 | 154K | 403K | 38.3% | 0 |
| 2026-10-06 | 175K | 396K | 44.2% | 150 |
| 2026-10-05 | 184K | 380K | 48.4% | 0 |
| 2026-10-02 | 243K | 469K | 51.7% | 0 |
| 2026-10-01 | 272K | 562K | 48.4% | 0 |
| 2026-09-30 | 337K | 572K | 58.9% | 0 |
| 2026-09-29 | 306K | 577K | 53.0% | 0 |
| 2026-09-28 | 160K | 555K | 28.8% | 388 |
| 2026-09-25 | 283K | 502K | 56.4% | 0 |
| 2026-09-24 | 541K | 866K | 62.5% | 0 |
| 2026-09-23 | 612K | 974K | 62.8% | 0 |
| 2026-09-22 | 283K | 708K | 40.0% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 25 August 2026, the fails-to-deliver balance in SNDX is 466 shares, down 12,988 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (4 February 2026) to 233,974 shares (1 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-25 | 466 | $19.57 | $9K |
| 2026-08-18 | 13,454 | $19.76 | $266K |
| 2026-08-14 | 3,718 | $19.08 | $71K |
| 2026-08-10 | 42 | $20.40 | $857 |
| 2026-08-07 | 58,200 | $19.76 | $1.2M |
| 2026-08-06 | 2,862 | $19.92 | $57K |
| 2026-07-20 | 6,939 | $22.80 | $158K |
| 2026-07-16 | 4,760 | $23.52 | $112K |
| 2026-07-15 | 1,115 | $24.13 | $27K |
| 2026-07-13 | 5 | $23.61 | $118 |
| 2026-07-07 | 99 | $22.08 | $2K |
| 2026-07-01 | 233,974 | $21.86 | $5.1M |
| 2026-06-30 | 55,850 | $21.78 | $1.2M |
| 2026-06-29 | 16,050 | $21.31 | $342K |
| 2026-06-24 | 4,856 | $19.61 | $95K |
| 2026-06-23 | 59,645 | $19.32 | $1.2M |
| 2026-06-22 | 62,569 | $19.00 | $1.2M |
| 2026-06-18 | 62,910 | $19.04 | $1.2M |
| 2026-06-15 | 974 | $18.25 | $18K |
| 2026-06-05 | 101,152 | $18.02 | $1.8M |
| 2026-06-04 | 567 | $18.34 | $10K |
| 2026-05-28 | 667 | $19.61 | $13K |
| 2026-05-01 | 8,554 | $21.43 | $183K |
| 2026-03-31 | 22,689 | $22.48 | $510K |
| 2026-03-26 | 22 | $24.20 | $532 |
| 2026-03-23 | 77 | $24.23 | $2K |
| 2026-03-02 | 60 | $21.71 | $1K |
| 2026-02-09 | 2,627 | $21.01 | $55K |
| 2026-02-04 | 3 | $21.25 | $64 |
| 2026-01-30 | 754 | $20.59 | $16K |
Insider trades
SEC Form 4, newest first. JSONInsiders at SNDX reported 1 open-market sell worth $114K in the last 90 days and no open-market buys. Latest filing: Podlesak Dennis (Director) on 2026-10-29.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-29 | Podlesak Dennis | Director | Sell | 8K | $14.21 | $114K | 240K |
| 2026-10-29 | Podlesak Dennis | Director | Exercise or conversion | 8K | $11.81 | $94K | 248K |
| 2026-07-08 | Metzger Michael A | Chief Executive Officer | Sell | 32K | $24.24 | $785K | 485K |
| 2026-07-08 | Metzger Michael A | Chief Executive Officer | Exercise or conversion | 32K | $6.38 | $207K | 517K |
| 2026-06-12 | Botwood Nicholas A.J. | Head of R&D, CMO | Sell | 31K | $18.14 | $567K | 61K |
| 2026-06-12 | Botwood Nicholas A.J. | Head of R&D, CMO | Exercise or conversion | 31K | $13.82 | $432K | 92K |
| 2026-06-11 | Botwood Nicholas A.J. | Head of R&D, CMO | Sell | 34K | $18.00 | $617K | 61K |
| 2026-06-11 | Botwood Nicholas A.J. | Head of R&D, CMO | Exercise or conversion | 23K | $13.82 | $311K | 95K |
| 2026-06-01 | Metzger Michael A | Chief Executive Officer | Sell | 7K | $18.99 | $130K | 485K |
| 2026-06-01 | Goldan Keith A. | Chief Financial Officer | Sell | 1K | $18.99 | $22K | 139K |
| 2026-02-09 | Metzger Michael A | Chief Executive Officer | Sell | 17K | $21.03 | $361K | 492K |
| 2026-02-09 | Goldan Keith A. | Chief Financial Officer | Sell | 3K | $21.03 | $72K | 140K |
| 2026-02-06 | Metzger Michael A | Chief Executive Officer | Sell | 7K | $20.62 | $153K | 509K |
| 2026-02-06 | Goldan Keith A. | Chief Financial Officer | Sell | 2K | $20.62 | $43K | 144K |
| 2026-02-04 | Rizo Aleksandra | Director | Grant | 24K | $0.00 | $0 | 49K |
| 2026-02-04 | Podlesak Dennis | Director | Grant | 48K | $0.00 | $0 | 240K |
| 2026-02-04 | Metzger Michael A | Chief Executive Officer | Grant | 145K | $0.00 | $0 | 516K |
| 2026-02-04 | Metzger Michael A | Chief Executive Officer | Grant | 73K | $0.00 | $0 | 372K |
| 2026-02-04 | Legault Pierre | Director | Grant | 24K | $0.00 | $0 | 114K |
| 2026-02-04 | Katkin Keith | Director | Grant | 24K | $0.00 | $0 | 124K |
| 2026-02-04 | Jarrett Jennifer | Director | Grant | 24K | $0.00 | $0 | 114K |
| 2026-02-04 | Huber Martin H. Jr. | Director | Grant | 24K | $0.00 | $0 | 103K |
| 2026-02-04 | Goldan Keith A. | Chief Financial Officer | Grant | 31K | $0.00 | $0 | 146K |
| 2026-02-04 | Goldan Keith A. | Chief Financial Officer | Grant | 22K | $0.00 | $0 | 115K |
| 2026-02-04 | Botwood Nicholas A.J. | Head of R&D, CMO | Grant | 36K | $0.00 | $0 | 95K |
| 2026-02-04 | Botwood Nicholas A.J. | Head of R&D, CMO | Grant | 24K | $0.00 | $0 | 59K |
| 2026-01-30 | Goldan Keith A. | Chief Financial Officer | Other transaction | 1K | $8.48 | $10K | 94K |
| 2025-12-01 | Goldan Keith A. | Chief Financial Officer | Gift | 1K | $0.00 | $0 | 92K |
| 2025-09-08 | Metzger Michael A | Chief Executive Officer | Sell | 157K | $16.41 | $2.6M | 299K |
| 2025-09-08 | Metzger Michael A | Chief Executive Officer | Exercise or conversion | 157K | $10.90 | $1.7M | 456K |
| 2025-08-18 | Podlesak Dennis | Director | Sell | 19K | $15.84 | $304K | 192K |
| 2025-08-18 | Podlesak Dennis | Director | Exercise or conversion | 19K | $7.20 | $138K | 211K |
| 2025-08-15 | Podlesak Dennis | Director | Sell | 19K | $15.54 | $298K | 192K |
| 2025-08-15 | Podlesak Dennis | Director | Exercise or conversion | 19K | $7.20 | $138K | 211K |
| 2025-08-14 | Podlesak Dennis | Director | Sell | 19K | $14.19 | $273K | 192K |
| 2025-08-14 | Podlesak Dennis | Director | Exercise or conversion | 19K | $7.20 | $138K | 211K |
| 2025-07-31 | Goldan Keith A. | Chief Financial Officer | Other transaction | 1K | $8.43 | $10K | 94K |
| 2025-07-16 | Metzger Michael A | Chief Executive Officer | Sell | 8K | $9.29 | $70K | 299K |
| 2025-07-16 | Goldan Keith A. | Chief Financial Officer | Sell | 1K | $9.29 | $12K | 92K |
| 2025-05-19 | Katkin Keith | Director | Buy | 10K | $9.11 | $91K | 100K |
| 2025-05-19 | Huber Martin H. Jr. | Director | Buy | 5K | $8.99 | $45K | 79K |
| 2025-05-19 | Goldan Keith A. | Chief Financial Officer | Buy | 3K | ≈ $9.06, midpoint of the stated range $8.85 to $9.28 | ≈ $27K | 94K |
| 2025-05-16 | Botwood Nicholas A.J. | Head of R&D, CMO | Buy | 12K | $9.00 | $106K | 35K |
| 2025-03-14 | Metzger Michael A | Chief Executive Officer | Exercise or conversion | 6K | $7.20 | $44K | 306K |
| 2025-03-04 | Metzger Michael A | Chief Executive Officer | Exercise or conversion | 8K | $7.20 | $56K | 308K |
| 2025-03-04 | Metzger Michael A | Chief Executive Officer | Sell | 8K | $15.05 | $118K | 300K |
| 2025-02-10 | Gallagher Neil | President, Head of R&D | Sell | 5K | $15.50 | $72K | 85K |
| 2025-02-10 | Metzger Michael A | Chief Executive Officer | Sell | 13K | $15.50 | $206K | 300K |
| 2025-02-10 | Goldan Keith A. | Chief Financial Officer | Sell | 4K | $15.50 | $59K | 91K |
| 2025-02-05 | Legault Pierre | Director | Grant | 25K | $0.00 | $0 | 90K |
| 2025-02-05 | Huber Martin H. Jr. | Director | Grant | 25K | $0.00 | $0 | 74K |
| 2025-02-05 | Jarrett Jennifer | Director | Grant | 25K | $0.00 | $0 | 90K |
| 2025-02-05 | Katkin Keith | Director | Grant | 25K | $0.00 | $0 | 90K |
| 2025-02-05 | Meury William | Director | Grant | 25K | $0.00 | $0 | 90K |
| 2025-02-05 | Rizo Aleksandra | Director | Grant | 25K | $0.00 | $0 | 25K |
| 2025-02-05 | Podlesak Dennis | Director | Grant | 50K | $0.00 | $0 | 192K |
| 2025-02-05 | Metzger Michael A | Chief Executive Officer | Grant | 61K | $0.00 | $0 | 224K |
| 2025-02-05 | Metzger Michael A | Chief Executive Officer | Grant | 89K | $0.00 | $0 | 313K |
| 2025-02-05 | Goldan Keith A. | Chief Financial Officer | Grant | 23K | $0.00 | $0 | 95K |
| 2025-02-05 | Goldan Keith A. | Chief Financial Officer | Grant | 19K | $0.00 | $0 | 71K |
| 2025-02-05 | Gallagher Neil | President, Head of R&D | Grant | 19K | $0.00 | $0 | 66K |
| 2025-02-05 | Gallagher Neil | President, Head of R&D | Grant | 23K | $0.00 | $0 | 90K |
| 2024-06-14 | Goldan Keith A. | Chief Financial Officer | Buy | 1K | $20.03 | $25K | 53K |
| 2024-02-07 | Legault Pierre | Director | Grant | 17K | $0.00 | $0 | 65K |
| 2024-02-07 | Podlesak Dennis | Director | Grant | 34K | $0.00 | $0 | 142K |
| 2024-02-07 | Morrison Briggs | Director | Grant | 17K | $0.00 | $0 | 35K |
| 2024-02-07 | Meury William | Director | Grant | 17K | $0.00 | $0 | 65K |
| 2024-02-07 | Katkin Keith | Director | Grant | 17K | $0.00 | $0 | 65K |
| 2024-02-07 | Jarrett Jennifer | Director | Grant | 17K | $0.00 | $0 | 65K |
| 2024-02-07 | Huber Martin H. Jr. | Director | Grant | 17K | $0.00 | $0 | 49K |
| 2024-02-07 | Gallagher Neil | President, Head of R&D | Grant | 13K | $0.00 | $0 | 48K |
| 2024-02-07 | Gallagher Neil | President, Head of R&D | Grant | 35K | $0.00 | $0 | 35K |
| 2024-02-07 | Goldan Keith A. | Chief Financial Officer | Grant | 35K | $0.00 | $0 | 40K |
| 2024-02-07 | Goldan Keith A. | Chief Financial Officer | Grant | 12K | $0.00 | $0 | 51K |
| 2024-02-07 | Metzger Michael A | Chief Executive Officer | Grant | 39K | $0.00 | $0 | 164K |
| 2024-02-07 | Metzger Michael A | Chief Executive Officer | Grant | 107K | $0.00 | $0 | 125K |
| 2024-01-31 | Goldan Keith A. | Chief Financial Officer | Other transaction | 1K | $17.42 | $21K | 5K |
| 2023-08-09 | Morrison Briggs | Director | Exercise or conversion | 53K | $8.77 | $464K | 71K |
| 2023-08-09 | Morrison Briggs | Director | Sell | 53K | $18.27 | $966K | 18K |
| 2023-08-02 | Meury William | Director | Sell | 24K | $20.45 | $491K | 48K |
| 2023-08-02 | Meury William | Director | Exercise or conversion | 24K | $9.47 | $227K | 72K |
| 2023-08-02 | Meury William | Director | Sell | 35K | $20.46 | $716K | 48K |
| 2023-08-02 | Meury William | Director | Exercise or conversion | 24K | $9.47 | $227K | 72K |
| 2023-08-02 | Meury William | Director | Exercise or conversion | 35K | $7.11 | $249K | 83K |
| 2023-08-02 | Meury William | Director | Sell | 24K | $20.45 | $491K | 48K |
| 2023-07-31 | Goldan Keith A. | Chief Financial Officer | Other transaction | 862 | $18.12 | $16K | 3K |
| 2023-07-10 | Morrison Briggs | Director | Exercise or conversion | 53K | $8.77 | $464K | 71K |
| 2023-07-10 | Morrison Briggs | Director | Sell | 53K | $20.40 | $1.1M | 18K |
| 2023-06-13 | Goldan Keith A. | Chief Financial Officer | Sell | 577 | $22.31 | $13K | 3K |
| 2023-06-09 | Morrison Briggs | Director | Exercise or conversion | 28K | $8.77 | $248K | 71K |
| 2023-06-09 | Morrison Briggs | Director | Exercise or conversion | 25K | $6.38 | $157K | 42K |
| 2023-06-09 | Morrison Briggs | Director | Sell | 25K | $21.18 | $521K | 46K |
| 2023-06-09 | Morrison Briggs | Director | Sell | 28K | $21.18 | $599K | 18K |
| 2023-05-09 | Morrison Briggs | Director | Sell | 53K | $21.41 | $1.1M | 18K |
| 2023-05-09 | Morrison Briggs | Director | Exercise or conversion | 53K | $6.38 | $337K | 71K |
| 2023-04-10 | Morrison Briggs | Director | Sell | 53K | $19.53 | $1.0M | 18K |
| 2023-04-10 | Morrison Briggs | Director | Exercise or conversion | 53K | $6.38 | $337K | 71K |
| 2023-03-13 | Morrison Briggs | President, Head of R&D | Exercise or conversion | 53K | $6.38 | $337K | 71K |
| 2023-03-13 | Morrison Briggs | President, Head of R&D | Sell | 53K | $22.53 | $1.2M | 18K |
| 2023-02-15 | Ordentlich Peter | Chief Scientific Officer | Sell | 17K | $25.84 | $450K | 0 |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON10 Form 144 notices on file for SNDX worth $2.8M at the prices reported; 1 in the last 90 days worth $115K. Latest: DENNIS G PODLESAK filed on 2026-10-29 to sell 8,000 shares ($115K) from 2026-10-29.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-29 | DENNIS G PODLESAKDirector | 8K | $115K | 0.009% | 2026-10-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-08 | MICHAEL METZGERDirector, Officer | 32K | $752K | 0.037% | 2026-07-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-12 | Botwood Nicholas A.J.Officer | 31K | $567K | 0.035% | 2026-06-12 | Fidelity Brokerage Services LLC |
| 2026-06-11 | Botwood Nicholas A.J.Officer | 34K | $609K | 0.039% | 2026-06-11 | Fidelity Brokerage Services LLC |
| 2026-06-01 | Metzger Michael AOfficer, Director | 7K | $130K | 0.008% | 2026-06-01 | Fidelity Brokerage Services LLC |
| 2026-06-01 | Goldan Keith A.Officer | 1K | $22K | 0.001% | 2026-06-01 | Fidelity Brokerage Services LLC |
| 2026-02-09 | Metzger Michael AOfficer, Director | 17K | $361K | 0.020% | 2026-02-09 | Fidelity Brokerage Services LLC |
| 2026-02-09 | Goldan Keith A.Officer | 3K | $72K | 0.004% | 2026-02-09 | Fidelity Brokerage Services LLC |
| 2026-02-06 | Metzger Michael AOfficer, Director | 7K | $153K | 0.009% | 2026-02-06 | Fidelity Brokerage Services LLC |
| 2026-02-06 | Goldan Keith A.Officer | 2K | $43K | 0.002% | 2026-02-06 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of SNDX in their latest filing, all on Schedule 13G (passive). The largest reported stake is STATE STREET CORPORATION at 6.4% of the class (5,658,465 shares), filed 2026-08-07 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 5.7M | 6.4% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 1 | Steven A. Cohenindividual | 2.0M | 2.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Point72 Capital Advisors, Inc.corporation | 2.0M | 2.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Point72 Asset Management, L.P.partnership | 2.0M | 2.3% | 2026-03-31 |
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 4.5M | 5.0% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding SNDX at their latest 13F. JSON6 of the 30 tracked managers held SNDX at their latest 13F, $137.8M in total at quarter-end prices. Millennium Management is the largest at $44.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 5 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 2.1M | $44.9M | 0.02% | +1.9M |
| Two Sigma Investments | 2026-06-30 | 1.6M | $34.5M | 0.03% | -1K |
| D. E. Shaw & Co. | 2026-06-30 | 1.2M | $27.1M | 0.01% | -362K |
| AQR Capital Management | 2026-06-30 | 853K | $18.7M | 0.01% | -127K |
| Renaissance Technologies | 2026-06-30 | 322K | $7.0M | 0.01% | -177K |
| Citadel Advisors | 2026-06-30 | 258K | $5.6M | 0.00% | -373K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Syndax Pharmaceuticals reported revenue of $72.8M, up 91.8% from the same quarter a year earlier, and net loss of $49.4M (-0.55 diluted EPS). In FY 2025 it generated -$323.0M of operating cash flow. As of 2026-06-30, cash was $336.5M against $344.0M of debt.
- Cash
- $336.5M
- Debt
- $344.0M
- Equity
- $15.1M
- Total assets
- $703.7M
- Shares outstanding
- 89,297,086
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $72.8M | -$49.4M | -67.8% | -0.55 |
| Q1 FY 2026 | 2026-03-31 | $64.9M | -$42.7M | -65.8% | -0.48 |
| Q4 FY 2025derived | 2025-12-31 | $68.5M | -$68.0M | -99.3% | n/a |
| Q3 FY 2025 | 2025-09-30 | $45.9M | -$60.7M | -132.4% | -0.70 |
| Q2 FY 2025 | 2025-06-30 | $38.0M | -$71.8M | -189.3% | -0.83 |
| Q1 FY 2025 | 2025-03-31 | $20.0M | -$84.8M | -423.3% | -0.98 |
| Q4 FY 2024derived | 2024-12-31 | $7.7M | -$94.2M | -1226.2% | n/a |
| Q3 FY 2024 | 2024-09-30 | $12.5M | -$84.1M | -673.0% | -0.98 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $172.4M | -$285.4M | -$323.0M | $187K | n/a | n/a |
| FY 2024 | 2024-12-31 | $23.7M | -$318.8M | -$274.9M | $0 | n/a | n/a |
| FY 2023 | 2023-12-31 | $0 | -$209.4M | -$160.6M | $0 | n/a | n/a |
| FY 2022 | 2022-12-31 | $0 | -$149.3M | -$133.7M | $0 | n/a | n/a |
| FY 2021 | 2021-12-31 | $139.7M | $24.9M | $29.1M | $129K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Syndax Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Syndax Pharmaceuticals (SNDX), SEC CIK 1395937, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-08-25.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-29.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-11-02.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-29.JSON and CSV
- Company record
- EDGAR filing index for CIK 1395937Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of SNDX is sold short?
18,001,644 shares were held short at the 2026-10-15 settlement, 7.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is SNDX's daily short volume?
On 2026-11-02, 504,165 of the 1,040,633 SNDX shares reported to FINRA were sold short, 48.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does SNDX have fails to deliver?
The SEC's latest file shows 466 SNDX shares failed to deliver at settlement 2026-08-25. Fails are reported per settlement date and published twice a month with a lag.
Are SNDX insiders buying or selling?
Insiders at SNDX reported 1 open-market sell worth $114K in the last 90 days and no open-market buys. Latest filing: Podlesak Dennis (Director) on 2026-10-29.
Have SNDX insiders filed to sell?
10 Form 144 notices on file for SNDX worth $2.8M at the prices reported; 1 in the last 90 days worth $115K. Latest: DENNIS G PODLESAK filed on 2026-10-29 to sell 8,000 shares ($115K) from 2026-10-29.
Who owns 5% or more of SNDX?
2 holders report 5% or more of SNDX in their latest filing, all on Schedule 13G (passive). The largest reported stake is STATE STREET CORPORATION at 6.4% of the class (5,658,465 shares), filed 2026-08-07 for an event on 2026-06-30.
What did SNDX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Syndax Pharmaceuticals reported revenue of $72.8M, up 91.8% from the same quarter a year earlier, and net loss of $49.4M (-0.55 diluted EPS). In FY 2025 it generated -$323.0M of operating cash flow. As of 2026-06-30, cash was $336.5M against $344.0M of debt.
Which tracked 13F managers own SNDX?
6 of the 30 tracked 13F managers held SNDX shares at their latest filing, $137.8M in all. The largest: Izzy Englander's Millennium Management (2.1M shares, $44.9M), Two Sigma Investments (1.6M shares, $34.5M), D. E. Shaw & Co. (1.2M shares, $27.1M), Cliff Asness's AQR Capital Management (853K shares, $18.7M), Renaissance Technologies (322K shares, $7.0M), Ken Griffin's Citadel Advisors (258K shares, $5.6M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.